KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) Debt to Equity: 2009-2017

Historic Debt to Equity for Arbutus Biopharma (ABUS) over the last 2 years, with Dec 2017 value amounting to $0.07.

  • Arbutus Biopharma's Debt to Equity rose 11.25% to $0.07 in Q4 2017 from the same period last year, while for Dec 2017 it was $0.07, marking a year-over-year increase of 11.25%. This contributed to the annual value of $0.07 for FY2017, which is 11.25% up from last year.
  • Latest data reveals that Arbutus Biopharma reported Debt to Equity of $0.07 as of Q4 2017, which was down 8.27% from $0.07 recorded in Q3 2017.
  • Arbutus Biopharma's 5-year Debt to Equity high stood at $29,122 for Q4 2013, and its period low was $0.06 during Q4 2016.
  • Over the past 2 years, Arbutus Biopharma's median Debt to Equity value was $0.07 (recorded in 2017), while the average stood at $0.07.
  • In the last 5 years, Arbutus Biopharma's Debt to Equity slumped by 32.70% in 2013 and then increased by 11.25% in 2017.
  • Quarterly analysis of 3 years shows Arbutus Biopharma's Debt to Equity stood at $29,122 in 2013, then reached $0.06 in 2016, then increased by 11.25% to $0.07 in 2017.
  • Its Debt to Equity stands at $0.07 for Q4 2017, versus $0.07 for Q3 2017 and $0.07 for Q2 2017.